盐酸安罗替尼治疗晚期非小细胞肺癌的研究进展  

Research advances of Anlotinib in the treatment of advanced none-small cell lung cancer

作　　者：夏波[1] 程志祥[1] XIA Bo;CHENG Zhixiang(Department of Pain Management,the Second Affiliated Hospital,Nanjing Medical University,Jiangsu Province,Nanjing210011,China)

机构地区：[1]南京医科大学第二附属医院疼痛科,江苏南京210011

出　　处：《中国医药导报》2020年第30期53-55,63,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(81372395)。

摘　　要：血管新生是肿瘤细胞增殖、生长、转移过程中重要组成环节,抗血管生成药物在肿瘤治疗中起重要作用。安罗替尼是我国自主研发的新型小分子多靶点络氨酸激酶抑制剂,能高效抑制血管内皮生长因子受体、血小板衍生生长因子受体、纤维母细胞生长因子受体、干细胞因子受体等多个靶点,具有全面阻断肿瘤血管新生并抑制肿瘤生长的作用,毒副作用低。多项临床试验已证实安罗替尼在晚期非小细胞肺癌中具有良好的疗效及安全性。本文通过复习相关文献,对近年来安罗替尼在抗肿瘤机制、疗效及安全性研究、疗效预测因子、耐药机制方面的进展进行综述。Angiogenesis is an important segment in the process of multiplication,invasion,and metastasis of malignant tumor cells.Anti-angiogenic drug plays an important role in the treatment of cancer.Anlotinib is a new small molecule multi-target anti-angiogenesis drug tyrosine kinase inhibitor developed independently in China.It can effectively inhibit such as vascular endothelial growth factor receptor,platelet-derived growth factor receptor,fibroblast growth factor receptor,c-kitproto-oncogeneprotein and so on to completely block tumor angiogenesis and inhibit tumor growth with low toxic and side effects.Several clinical trials confirm that Anlotinib has promising efficacy and safety in advanced non-small cell lung cancer.This paper summarizes the current knowledge of Anlotinib in anti-tumor mechanism,clinical efficacy and safety studies,efficacy predictive factors,and drug resistance mechanism in recent years.

关 键 词：安罗替尼 抗血管生成治疗 分子靶向药物 非小细胞肺癌 

分 类 号：R73[医药卫生—肿瘤]